The firm served as lead counsel on behalf of Oklahoma Medical Research Foundation in a patent infringement suit brought in the Northern District of Oklahoma against Alexion Pharmaceuticals. The patents related to complement-inhibition technology and their use in a drug marketed by Alexion to treat a rare, debilitating and life-threatening disease. After replacing OMRF’s previous counsel in the matter and soon after claim construction briefing was complete, we obtained a settlement. It included payment to our client as well as public acknowledgement that individuals affiliated with OMRF were the true inventors of the technology at issue.

Oklahoma Med. Research Found. v. Alexion Pharmaceuticals, Inc., No. 07-163 (N.D. Okla. filed Mar. 15, 2007).

Experience Center

Match our Experience to Your Needs

Experience Highlights

United States of America et al. v. Wachovia Bank and Trust Company, N.A.
The firm served as lead counsel on behalf of third party defendant, Achieve Bank N.A., and successfully argued the first reported case before the more
Breach of fiduciary duty case against employee of a Fortune 200 company
Successfully represented a Fortune 200 employer in trial and appeal against a former employee who engaged in self-dealing in breach of his more
Multi-currency syndicated senior revolving credit facility for provider of information solutions
Representation of publicly held provider of information solutions, as borrower, in connection with $500 million multi-currency syndicated senior more
Patent litigation for major tire manufacturer
The firm served as lead counsel on behalf of automobile manufacturers in a suit in the Western District of Wisconsin. The suit alleged that the more